The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy. Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. Landmark ZUMA-7 Study OS Data Reach Maturity Per Protocol, 5 Years After 1 st Patient Randomized. First and Only Treatment in Nearly 30 Years to Show Statistically Significant Improvement in OS for Initial Treatment of R/R LBCL Patients Versus Historical Standard of Care in Curative Setting. Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Sciences Statement on the Passing of the Honorable George P. Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees

Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission WadeĪll Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Gilead Receives Complete Response Letter from U.S. Gilead Enables Easier Veklury® (Remdesivir) Access Through Retail and Specialty Pharmacies for Long-Term Care and Skilled Nursing Facilities Gilead Sciences Commends Convictions in Counterfeiting Scheme Pledges Continued Commitment to Protect Patients Gilead Sciences Statement on Sustaining Access to AmBisome® in Low- and Middle-Income CountriesĬhristi Shaw to Depart Gilead and Kite Leadership End of Q1

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Human kite